Dr. Reddys Laboratories Ltd. | Date: 2016-11-22
Doxycycline formulations with a reduced food effect are disclosed. Particularly disclosed are modified release formulations which can be administered once a day and exhibit a reduced food effect. Methods of treating inflammatory conductions such as rosacea or inflammatory symptoms such as the papules and pustules of rosacea or acne vulgaris are also disclosed.
Dr. Reddys Laboratories Ltd. | Date: 2016-01-29
The present application relates to a method of treating migraine or cluster headache in a human patient, said method comprising administering subcutaneously composition comprising sumatriptan or its pharmaceutically acceptable salt, in an amount equivalent to 3 mg sumatriptan base.
DR. REDDYS LABORATORIES Ltd | Date: 2016-10-13
The present application relates to crystalline and amorphous forms of Enzalutamide. The present application further relates to amorphous solid dispersions of Enzalutamide with pharmaceutically acceptable carriers. The present application also relates to a process for the preparation of Form R1 of Enzalutamide.
Dr. Reddys Laboratories Ltd. | Date: 2016-11-10
The present invention provides a clear depot comprising at least one hydrophilic water-soluble pharmaceutically active agent selected from the group consisting of vancomycin, gentamicin, a pharmaceutically acceptable salt thereof and a mixture thereof, water, a phospholipid, an oil, optionally a pH adjusting agent, and a viscosity modifying agent selected from the group consisting of ethanol, isopropanol, and a mixture thereof, wherein the water present in the depot is no more than about 4 wt % relative to the total weight of the depot and the depot has a pH of between about 3 and about 6, method of making and administering same.
Dr. Reddys Laboratories Ltd. | Date: 2016-05-27
The present invention relates to a stable oral liquid pharmaceutical composition of celecoxib or its pharmaceutically acceptable salts thereof. The celecoxib present in the compositions as described herein do not show any precipitation when subjected in Fasted-State Simulated Gastric Fluid (FaSSGF) at pH 2.0, temperature of 37 C.0.5 C. and under stirring at a speed of 50 rpm at least for 60 minutes. It also relates to the process of preparing and method of using said composition of celecoxib.
Dr. Reddys Laboratories Ltd. | Date: 2016-08-18
Parenteral (injectable) celecoxib emulsions and nanoemulsions are disclosed as are their use to treat pain in patients so afflicted. The emulsions are generally oil in water emulsions often comprised of an oil phase including an oil and a lecithin wherein the mean droplet size of the discontinuous oil phase is about 200 nanometers or less.
Dr. Reddys Laboratories Ltd. | Date: 2016-09-12
The present application relates to a method for obtaining a mixture of estrogens from the pregnant mares urine.
Dr. Reddys Laboratories Ltd. | Date: 2016-09-19
The present invention relates to a series of substituted compounds having the general formula (I), including their stereoisomers and/or their pharmaceutically acceptable salts. wherein R^(1), R^(2), R^(3), R^(4), R^(5), and R^(6 )are as defined herein. This invention also relates to methods of making these compounds including intermediates. The compounds of this invention are effective at the kappa () opioid receptor (KOR) site. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic pain, and associated disorders, particularly functioning peripherally at the CNS.
Dr. Reddys Laboratories Ltd. and Dr. Reddys Laboratories Inc. | Date: 2016-04-20
The present invention provides methods of increasing the levels of low pl isoforms of expressing erythropoiesis stimulating protein in media containing metal ions, to improve product quality.
Dr. Reddys Laboratories Ltd. | Date: 2016-06-08
The present application relates to a series of substituted imidazo[1,2-a]pyridine compounds of formula (I), pharmaceutically acceptable salts, pharmaceutically acceptable solvates or stereoisomers thereof, their use as tropomyosin receptor kinase (Trk) family protein kinase inhibitors, method of making and pharmaceutical compositions comprising such compounds.